Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 2/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083729 | 0.90 | AURKB (0.57) | LMNAGAANPC1RAB9AALDH1A1 | |
| SCHEMBL14083769 | 0.89 | MEN1 (0.62) | LMNAALDH1A1POLBKMT2AKDM4E | |
| SCHEMBL14083788 | 0.88 | KCNQ3 (0.62) | LMNAALDH1A1POLBKMT2AMAPK1 | |
| SCHEMBL14083795 | 0.88 | SMN1; SMN2 (0.59) | LMNAGAARAB9AALDH1A1POLB | |
| SCHEMBL14083733 | 0.87 | HDAC8 (0.54) | LMNANPC1RAB9AALDH1A1POLB | |
| SCHEMBL14083835 | 0.87 | AURKB (0.56) | LMNANPC1RAB9AALDH1A1POLB | |
| SCHEMBL14083736 | 0.86 | NPC1 (0.57) | NPC1RAB9AALDH1A1KMT2ACSF1R | |
| SCHEMBL14083805 | 0.86 | POLB (0.60) | LMNANPC1RAB9AALDH1A1POLB | |
| SCHEMBL14083757 | 0.86 | GRM4 (0.63) | LMNANPC1RAB9AALDH1A1POLB | |
| SCHEMBL14083841 | 0.86 | AURKB (0.55) | LMNAALDH1A1POLBKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | LMNA 2619/4885GAA 3059/4885NPC1 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.